Financial Performance - The company's operating revenue for Q1 2024 was ¥1,117,297,002.98, representing a decrease of 11.59% compared to the same period last year[3] - Net profit attributable to shareholders of the listed company was ¥293,365,824.90, an increase of 24.00% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥281,649,753.39, reflecting a growth of 27.64%[3] - Basic earnings per share were ¥0.3123, up by 24.34% year-on-year[3] - Total operating revenue for Q1 2024 was CNY 1,118,140,673.81, a decrease of 11.6% compared to CNY 1,265,115,610.35 in Q1 2023[14] - Net profit for Q1 2024 reached CNY 293,272,864.09, representing an increase of 23.8% from CNY 237,011,521.21 in Q1 2023[15] - Operating profit for Q1 2024 was CNY 363,541,738.50, up 31.5% from CNY 276,344,505.52 in Q1 2023[15] Cash Flow - The net cash flow from operating activities was -¥103,296,907.81, which is a decline of 32.61% compared to the previous year[3] - Cash flow from operating activities was CNY 451,288,232.60 in Q1 2024, down 64.0% from CNY 1,254,861,762.57 in Q1 2023[17] - Net cash flow from operating activities was -$103.30 million, compared to -$153.28 million in the previous year, indicating an improvement of approximately 32.7%[18] - Total cash outflow from operating activities amounted to $554.59 million, down from $1.41 billion year-over-year, reflecting a decrease of about 60.7%[18] - The ending balance of cash and cash equivalents was $1.37 billion, compared to $824.84 million in the previous year, reflecting an increase of approximately 65.7%[19] - The net increase in cash and cash equivalents was -$80.42 million, an improvement from -$157.47 million in the previous year, indicating a reduction in cash outflow[19] Assets and Liabilities - Total assets at the end of the reporting period reached ¥12,880,364,470.24, an increase of 3.32% from the end of the previous year[4] - The total current assets reached RMB 7,626,089,907.84, up from RMB 7,167,666,681.72, indicating an increase of about 6.39%[11] - The total liabilities increased to RMB 4,546,366,012.75 from RMB 4,425,219,914.44, representing a growth of about 2.74%[13] - The company's equity attributable to shareholders reached RMB 7,841,814,179.64, up from RMB 7,548,383,235.96, reflecting an increase of approximately 3.88%[13] - The non-current assets totaled RMB 5,254,274,562.40, down from RMB 5,298,207,945.58, indicating a decrease of about 0.83%[11] Shareholder Returns - The company distributed $174.59 million in dividends, compared to $32.96 million in the previous year, showing a significant increase[19] - The company paid $267 million in debt repayments, down from $1.20 billion in the previous year, indicating a reduction of about 77.7%[19] Expenses - Research and development expenses decreased significantly to CNY 3,957,691.13 in Q1 2024 from CNY 14,040,635.04 in Q1 2023, a reduction of 71.8%[14] - The company reported a significant decrease in sales expenses, which fell to CNY 99,640,998.01 in Q1 2024 from CNY 250,719,922.47 in Q1 2023, a decline of 60.3%[14] Investment Income - The company experienced a loss in investment income of CNY -5,131,762.96 in Q1 2024, compared to a gain of CNY 677,078.11 in Q1 2023[15]

2023 年第三季度报告 单位：元 币种：人民币 1 / 13 证券代码：603567 证券简称：珍宝岛 黑龙江珍宝岛药业股份有限公司 2023 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期比 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|---------------------------|---------------------------|------------------|------------- ...

Dividend Distribution - The company plans to distribute a cash dividend of 2.00 CNY per 10 shares, totaling approximately 188.35 million CNY, which represents 39.84% of the net profit attributable to ordinary shareholders[3] - The company has a total share capital of 941,963,592 shares, with 137,232 shares held in the repurchase account not participating in the dividend distribution[3] Industry Performance - In 2023, the pharmaceutical industry experienced a revenue decline of 4% year-on-year, with profits decreasing by 16.2%[8] - The traditional Chinese medicine sector showed resilience, with Chinese patent medicine revenue increasing by 6.5% and profits rising by 6.4%[8] Market Trends and Health Expenditure - By the end of 2023, the total number of medical visits in China reached 9.56 billion, reflecting a year-on-year growth of 13.5%[8] - The national health expenditure in 2022 was 85,327 billion CNY, with a per capita expenditure of 6,044 CNY, marking an 11% increase year-on-year[8] Policy and Regulatory Environment - The new medical insurance directory will include 3,088 types of drugs, with significant increases in the inclusion of traditional Chinese medicine products[9] - The company is positioned to benefit from ongoing policy support for the development of traditional Chinese medicine, with 28 supportive measures recently introduced[9] - The company is actively participating in the accelerated and expanded centralized procurement process initiated by the National Medical Insurance Administration[9] Product Development and R&D - The company has achieved a total of 160 production licenses, covering 129 varieties, including 74 traditional Chinese medicine products and 55 chemical and biological drugs[10] - The company has introduced nine clinically advantageous products in major therapeutic areas, all included in the National Medical Insurance Directory, enhancing its product lineup[11] - The company has made significant progress in the R&D of traditional Chinese medicine, focusing on cardiovascular, digestive, respiratory, and immune categories, with one innovative drug in clinical trial application[13] - In the chemical drug sector, the company obtained marketing approvals for 10 projects, including 9 in China and 1 in the United States, with 6 registration applications accepted[14] Recognition and Awards - The company has been recognized in various rankings, including 26th among "Top 100 Chinese Traditional Medicine Enterprises" and 21st among "Top 30 Traditional Chinese Medicine Listed Companies" in 2022[10] - The company has been awarded the "Best Listed Company Board" at the 12th China Listed Company Summit Forum, highlighting its governance excellence[10] - The company has been included in the "2022 Green Manufacturing List" and recognized as a "National Level Green Factory," reflecting its commitment to sustainable practices[10] Market Strategy and Operations - The company has established a comprehensive product line from raw materials to biopharmaceuticals, enhancing its market competitiveness[10] - The company has successfully completed the transfer of the 10ml specification of Shuxue Ning injection, indicating strategic product management[10] - The company has established a nationwide marketing network and optimized its sales product structure, focusing on traditional Chinese medicine with key products including injection blood stasis solution and compound Qilan oral solution[15] - The company has successfully participated in multiple national drug procurement projects, with products like clindamycin hydrochloride capsules and injection inflammation solution selected in various provincial procurement initiatives[15] - The company has set up 16 local offices and 4 planting bases to enhance its control over upstream resources and customer development in the traditional Chinese medicine trade[16] - The company has implemented a centralized procurement model for raw materials, ensuring quality and cost-effectiveness through strategic partnerships with suppliers[17] - The production model is based on "sales-driven production," aligning production plans with sales forecasts and inventory levels to meet market demand[18] - The company operates over 5,000 types of pharmaceutical products, serving more than 1,400 downstream customers, enhancing its market position in medical distribution[21] - The company has developed a dual operating model for traditional Chinese medicine trade, focusing on "sales-driven procurement" and "variety management" to optimize inventory and sales strategies[22][23] - The company has established processing bases in key medicinal herb production areas, ensuring high-quality raw materials through fresh processing and storage[24] Financial Performance - The company's total assets increased by 6.75% to approximately ¥12.47 billion in 2023 compared to ¥11.68 billion in 2022[32] - Revenue decreased by 25.53% to approximately ¥3.14 billion in 2023 from ¥4.21 billion in 2022[32] - Net profit attributable to shareholders increased by 154.93% to approximately ¥472.74 million in 2023 compared to ¥185.44 million in 2022[32] - The market size for cardiovascular and respiratory traditional Chinese medicine reached approximately ¥100 billion annually, with the company holding the number one market share for its injection product in the cardiovascular field[27] - The company reported a net cash flow from operating activities of approximately -¥478.24 million in 2023, a decline of 46.34% from -¥326.79 million in 2022[32] - The weighted average return on net assets increased by 3.84 percentage points to 6.46% in 2023[34] - Basic earnings per share rose by 155.43% to ¥0.5032 in 2023 compared to ¥0.1970 in 2022[34] - The company is focusing on enhancing its product market value in key clinical areas, particularly cardiovascular and respiratory diseases, to drive sales growth[29] - The company is committed to optimizing its channel structure and improving marketing capabilities to expand market coverage and share[31] - The company achieved total operating revenue of CNY 3.138 billion, a year-on-year decrease of 25.53%[39] - The net profit attributable to shareholders of the listed company was CNY 473 million, a year-on-year increase of 154.93%[39] - In Q1, the operating revenue was CNY 1.264 billion, with a net profit of CNY 237 million; Q2 saw a revenue drop to CNY 287 million and a net loss of CNY 134 million[35] - The net cash flow from operating activities was negative across all quarters, with Q4 showing a net outflow of CNY 166 million[35] - The total number of ordinary shareholders at the end of the reporting period was 24,526, down from 24,767 the previous month[36] - The largest shareholder, Heilongjiang Chuangda Group Co., Ltd., holds 51.27% of the shares, with a reduction of 96.9 million shares during the reporting period[37] - The company has no preferred shareholders with restored voting rights as of the reporting period[38] - The company is focused on expanding its market presence and developing new products and technologies[39] - The company reported a significant increase in net profit despite a decline in revenue, indicating potential operational improvements[39] - There are no known related party transactions among the top shareholders, ensuring independent governance[38]

Financial Performance - The company's operating revenue for Q1 2023 was RMB 1,263,753,051.37, representing a year-on-year increase of 25.91%[2] - The net profit attributable to shareholders of the listed company reached RMB 236,593,220.04, up 49.76% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 220,655,889.02, reflecting a significant increase of 67.63%[2] - The basic earnings per share (EPS) was RMB 0.2512, which is an increase of 60.88% year-on-year[2] - Operating profit for Q1 2023 was ¥276,344,505.52, up 46.3% from ¥188,880,551.48 in Q1 2022[15] - Net profit for Q1 2023 amounted to ¥237,011,521.21, representing a 49.9% increase from ¥157,909,349.25 in Q1 2022[15] - Basic and diluted earnings per share for Q1 2023 were CNY 0.25, up from CNY 0.17 in Q1 2022, representing a growth of 47.06%[16] Cash Flow - The net cash flow from operating activities was negative at RMB -153,277,856.55, a decrease of 298.49% compared to the previous year[2] - Cash inflow from operating activities totaled CNY 963,550,607.24, slightly down from CNY 965,014,348.39 in the previous year[16] - Cash inflow from investment activities was CNY 20,040,359.64, down from CNY 25,000,849.15 in the previous year[17] - Net cash flow from investment activities improved to CNY 18,843,359.75 from a negative CNY 75,155,946.82 in Q1 2022[17] - Cash inflow from financing activities was CNY 1,205,000,000.00, significantly higher than CNY 430,000,000.00 in the previous year[17] - The net cash flow from financing activities was negative CNY 23,036,839.47, compared to a positive CNY 53,986,255.30 in Q1 2022[17] - The ending balance of cash and cash equivalents was CNY 824,842,855.30, down from CNY 1,500,174,546.91 in the previous year[17] Assets and Liabilities - Total assets at the end of the reporting period were RMB 12,057,546,810.00, showing a growth of 3.25% from the end of the previous year[3] - The equity attributable to shareholders of the listed company was RMB 7,335,154,395.93, an increase of 3.33% compared to the end of the previous year[3] - The total assets of the company as of March 31, 2023, amounted to RMB 12.06 billion, an increase from RMB 11.68 billion as of December 31, 2022[11] - The company's total current liabilities decreased to ¥3,454,888,708.77 from ¥3,866,737,710.44 year-over-year, a reduction of approximately 10.7%[12] - Long-term borrowings increased significantly to ¥1,020,000,000.00 from ¥460,000,000.00, marking a rise of 121.7%[12] - The company's retained earnings rose to ¥3,599,527,541.04 from ¥3,363,217,633.99, reflecting a growth of 7.0%[12] - The total equity attributable to shareholders increased to ¥7,335,154,395.93 from ¥7,098,966,761.17, an increase of 3.3% year-over-year[12] Share Repurchase - As of March 31, 2023, the company has repurchased a total of 2.5597 million shares, accounting for 0.27% of the total share capital, with a total payment of approximately RMB 29.99 million[9] - The highest share repurchase price was RMB 12.20 per share, while the lowest was RMB 10.96 per share[9] Market Conditions - The company experienced an increase in sales scale due to changes in market conditions, contributing to the profit growth[6] Non-Recurring Items - Non-recurring gains and losses totaled RMB 15,937,331.02 for the period[5] Research and Development - Research and development expenses for Q1 2023 were ¥14,040,635.04, up 27.4% from ¥11,020,378.79 in Q1 2022[14] - Sales expenses surged to ¥250,719,922.47, a substantial increase from ¥110,838,260.50 in the same quarter last year[14] Accounting Standards - The company did not apply new accounting standards or interpretations for the first time in 2023[18]

上海证券交易所 纪律处分决定书 〔2024〕136 号 关于对黑龙江珍宝岛药业股份有限公司、 控股股东黑龙江创达集团有限公司及 有关责任人予以通报批评的决定 ──────────────────────── 方同华，黑龙江珍宝岛药业股份有限公司时任董事长； 闫久江，黑龙江珍宝岛药业股份有限公司时任总经理； 王 磊，黑龙江珍宝岛药业股份有限公司时任财务负责人 （代行董事会秘书）； 张钟方，黑龙江珍宝岛药业股份有限公司时任董事会秘书。 一、上市公司及相关主体违规情况 当事人： 黑龙江珍宝岛药业股份有限公司，A 股证券简称：珍宝岛， A 股证券代码：603567； 黑龙江创达集团有限公司，黑龙江珍宝岛药业股份有限公司 控股股东； -1- 责任人方面，根据《警示函》认定，时任董事长方同华作为 公司主要负责人和信息披露事项的第一责任人，时任总经理闫久 江作为公司经营管理事项的具体负责人，时任财务负责人（代行 -3- 董事会秘书）王磊作为公司财务事项、信息披露事项的具体负责 人，时任董事会秘书张钟方作为公司信息披露事项的具体负责人， 未忠实勤勉履行职责，对公司违规行为负有责任。上述人员的行 为违反了《股票上市规则》第 2 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2024-045 黑龙江珍宝岛药业股份有限公司 关于控股股东非公开发行可交换公司债券 换股价格调整的提示性公告 近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"）收到公司控股 股东黑龙江创达集团有限公司（以下简称"创达集团"）的通知，创达集团 2023 年面向专业投资者非公开发行可交换公司债券（第二期）（以下简称"本期可交 债"）换股价格将进行调整，现将有关事项公告如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、控股股东可交换公司债券的基本情况 公司控股股东创达集团已于 2023 年 6 月 28 日完成本期可交债的发行。本期 可交债简称"23 创 02EB"，债券代码为"137177"，发行规模 0.9 亿元，债券期 限 3 年。具体内容详见公司于 2023 年 6 月 30 日在上海证券交易所网站披露的临 2023-059 号公告。 二、控股股东可交换公司债券本次换股价格调整情况 特此公告。 黑龙江珍宝岛药业股份有限公司董事会 2024 年 7 月 2 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2024-046 黑龙江珍宝岛药业股份有限公司 截至本公告日，吴弘先生不持有公司股份，不存在应当履行而未履行的承诺 事项。吴弘先生辞职不会影响公司相关工作的正常开展。公司董事会将根据《上 海证券交易所股票上市规则》等相关规定，尽快聘任符合任职资格的人员担任证 券事务代表，协助董事会秘书开展工作。 特此公告。 黑龙江珍宝岛药业股份有限公司董事会 2024 年 7 月 20 日 1 关于证券事务代表离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 黑龙江珍宝岛药业股份有限公司（以下简称"公司"）董事会于近日收到公 司证券事务代表吴弘先生提出的辞职报告，吴弘先生因个人原因辞去公司证券事 务代表职务，辞职报告自送达董事会之日起生效。吴弘先生辞职后将不在公司及 子公司担任任何职务。公司及董事会对吴弘先生在任职期间为公司发展做出的贡 献表示衷心的感谢。 ...

近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"）收到国家药品 监督管理局核准签发的盐酸溴己新注射液《药品注册证书》（证书编号： 2024S01637），现就相关情况公告如下： 证券代码：603567 证券简称：珍宝岛 公告编号：临 2024-044 黑龙江珍宝岛药业股份有限公司 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、药品的基本情况 药品名称：盐酸溴己新注射液 剂型：注射剂 注册分类：化学药品 3 类 药品注册标准编号：YBH14962024 证书编号：2024S01637 药品有效期：24 个月 处方药/非处方药：处方药 上市许可持有人：黑龙江珍宝岛药业股份有限公司 生产企业：黑龙江珍宝岛药业股份有限公司 药品批准文号：国药准字 H20244392 药品批准文号有效期：至 2029 年 07 月 08 日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。药品生产企 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2024-043 黑龙江珍宝岛药业股份有限公司 关于控股股东部分股份解除质押及再质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、股份质押及解除质押情况 （一）本次股份解除质押情况 创达集团于 2023 年 7 月 10 日将其所持有的公司 110,000,000 股无限售流 通股质押给龙江银行股份有限公司哈尔滨东大直支行（以下简称"龙江银行"）， 质押期限一年（具体内容详见公司在上海证券交易所网站披露的临 2023-065 号 公告）。创达集团于 2024 年 7 月 10 日办理了解除质押，具体情况如下： | 股东名称 | 黑龙江创达集团有限公司 | | --- | --- | | 本次解除质押股份 | 110,000,000 股 | | 占其所持股份比例 | 19.05% | | 占公司总股本比例 | 11.68% | | 解除质押时间 | 2024 年 7 月 10 日 | | 持股数量 | 577,315,294 股 | | 持股比例 | 61.3 ...

Summary of the Conference Call for Zhenbao Island Company Overview - Zhenbao Island was established in 1996 and listed on the Shanghai Stock Exchange in 2015. The company focuses on high-end formulations and the industrialization of traditional Chinese medicine, aiming to build a full industry chain advantage [4][5]. Industry and Market Position - The company operates primarily in the pharmaceutical industry, with a strong emphasis on traditional Chinese medicine. It has a clear development strategy that includes a dual-platform approach and a six-in-one operational layout [5][12]. - Zhenbao Island has six core traditional Chinese medicine injections and three exclusive products that significantly contribute to its revenue. The company ranks among the top in market share and has favorable pricing compared to competitors [6][10]. Financial Performance - In 2023, Zhenbao Island reported a revenue of 3.138 billion yuan, with a net profit of 472 million yuan, marking a year-on-year increase of 155% [8][10]. - For Q1 2024, the net profit was 230 million yuan, reflecting a 15% year-on-year growth [9][10]. - The pharmaceutical industrial segment's revenue increased by 85% year-on-year in 2023, with several core products experiencing rapid growth [10][12]. Product Development and Pipeline - The company is advancing a core product, a Class 1.1 new drug, which has recently received clinical trial approval. It has also completed acquisitions of 41 core products [7][12]. - Zhenbao Island is actively exploring new business models in the traditional Chinese medicine sector, including order-based business and warehouse operations [7][12]. Strategic Initiatives - The company is focusing on enhancing product quality and expanding its product line through secondary development and new drug development. It aims to optimize its product structure and increase market competitiveness [31][32]. - Zhenbao Island is also developing a supply chain for traditional Chinese medicine, collaborating with local governments to promote industry upgrades [33][62]. Future Outlook - The company anticipates a revenue target of 3 to 3.5 billion yuan for 2024, with a profit expectation of around 800 million yuan [42][43]. - Zhenbao Island is optimistic about the future of the traditional Chinese medicine sector, especially with recent supportive government policies and increasing public trust in traditional medicine [54][55]. Key Challenges and Considerations - The company acknowledges the impact of recent economic conditions on its operations but remains confident in meeting its annual targets [38][39]. - Zhenbao Island is adjusting its sales strategies and enhancing its marketing efforts to drive growth in its core product lines [46][47]. Conclusion - Zhenbao Island is positioned as a leading player in the traditional Chinese medicine market, with a robust growth strategy and a strong product pipeline. The company is focused on leveraging its strengths in research and development to capitalize on emerging opportunities in the pharmaceutical industry [61][62].